Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Joël Ezenfis"'
Autor:
Karima Chafai, Vanessa Balla, Hamida Oumbiche, Joël Ezenfis, Alfred Penfornis, Coralie Amadou
Publikováno v:
Annales d'Endocrinologie. 83:264-267
Publikováno v:
Médecine des Maladies Métaboliques. 15:398-401
Resume L’hyperglycemie est un des effets secondaires les plus frequents de l’alpelisib, un inhibiteur de la sous-unite alpha de la phosphatidylinositol-3-kinase, utilise dans le traitement des cancers du sein metastatiques hormono-dependants avec
Autor:
Charlotte Paul, Patrick R. Benusiglio, Jean Pierre Lotz, Erell Guillerm, Florence Coulet, Sophie Geoffron, Roseline Vibert, Sandrine Richard, Joël Ezenfis, Nathalie Chabbert-Buffet, Veronique Byrde, Noémie Basset, Joseph Gligorov, Manon Lejeune, Clément Korenbaum
Publikováno v:
European Journal of Medical Genetics
European Journal of Medical Genetics, 2020, 63, pp.104098-. ⟨10.1016/j.ejmg.2020.104098⟩
European Journal of Medical Genetics, Elsevier, 2020, 63, pp.104098-. ⟨10.1016/j.ejmg.2020.104098⟩
European Journal of Medical Genetics, 2020, 63, pp.104098-. ⟨10.1016/j.ejmg.2020.104098⟩
European Journal of Medical Genetics, Elsevier, 2020, 63, pp.104098-. ⟨10.1016/j.ejmg.2020.104098⟩
International audience; Introduction: Mainstreamed genetic testing (MGT) obviates the need for a cancer genetics consultation, since trained oncologists (O) and gynaecologists (G) provide counseling, prescribe testing and deliver results. We report r
Publikováno v:
European Journal of Gastroenterology & Hepatology. 11:1013-1018
OBJECTIVE Increased nitric oxide (NO) has been demonstrated in inflammatory bowel diseases (IBD). Plasma and urinary nitrite and nitrate are usually considered to reflect global NO generation. Recently it has been suggested that plasma nitrate may be
Autor:
Julien, Taïeb, Thierry, Lecomte, Joël, Ezenfis, Pascal, Artru, Emmanuel, Mitry, Valérie, Boige, Marie Christine, Clavero-Fabri, Jean-Nicolas, Vaillant, Philippe, Rougier, Michel, Ducreux
Publikováno v:
Gastroenterologie clinique et biologique. 26(6-7)
To prospectively evaluate efficacy and tolerance of the 5-fluorouracil + folinic acid + cisplatin (LV5FU2-P) combination in the treatment of unresectable pancreatic carcinoma.Between March 1998 and June 2000, 35 patients, mean age 61 years (37-75), w